Compare ON Holding AG (ONON) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs 10X Genomics Inc — how do they compare? ON Holding AG trades at $35.09 (market cap $11.38B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: ON Holding AG and 10X Genomics Inc are close in size by market cap, and 10X Genomics Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and 10X Genomics Inc for 91 Days on average.
| ONON | TXG | |
|---|---|---|
Market Cap | $11.38B | $10.07B |
Volume | 13,732,872 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $97.74 |
52-Week Low | $26.76 | $11.48 |
Typical Hold Time | 22 Days | 91 Days |
Enterprise Value | $10.54B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $34.04, up 2.47% today, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding the $0.4203 estimate. Revenue reached $3.01B in 2025, with net income of $203.70M, and profitability metrics like a 64.82% gross margin and 23.95% ROE indicate operational strength. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, supported by analyst consensus with a $42.26 price target and 74% buy ratings. Key opportunities include direct-to-consumer growth and expansion into new sports categories, while risks involve competitive pressures and execution of long-term goals amid market volatility.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
